for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Knight Therapeutics Inc

GUD.TO

Latest Trade

7.72CAD

Change

0.09(+1.18%)

Volume

431,740

Today's Range

7.66

 - 

7.81

52 Week Range

7.10

 - 

8.88

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Knight Therapeutics Inc Says Co, Medison Biotech (1995) Ltd Have Agreed To Separate Their Businesses

Nov 21 (Reuters) - Knight Therapeutics Inc <GUD.TO>::KNIGHT THERAPEUTICS INC - CO, MEDISON BIOTECH (1995) LTD HAVE AGREED TO SEPARATE THEIR BUSINESSES.KNIGHT THERAPEUTICS - KNIGHT WILL SELL TO MEDISON GROUP ALL OF KNIGHT'S SHARES IN MEDISON, REFLECTING APPROXIMATELY 28.3% OF SHARE CAPITAL OF MEDISON.KNIGHT THERAPEUTICS INC - KNIGHT WILL SELL TO MEDISON GROUP ALL OF KNIGHT'S SHARES IN MEDISON IN CONSIDERATION FOR C$77 MILLION PAYABLE IN CASH.KNIGHT THERAPEUTICS INC - CO, MEDISON AGREED TO RELEASE EACH OTHER FROM ALL CLAIMS AND WITHDRAW ALL LEGAL PROCEEDINGS INITIATED BY BOTH PARTIES.KNIGHT THERAPEUTICS INC - MEDISON AGREED TO A FOUR-YEAR STANDSTILL COMMITMENT AND WILL DIVEST ITS POSITION IN KNIGHT DURING THE FOUR-YEAR PERIOD.KNIGHT THERAPEUTICS INC - MEDISON, TOGETHER WITH ITS AFFILIATES OWN ABOUT 10.4 MILLION SHARES OR 7.5% OF KNIGHT.

Knight Therapeutics Inc- QTRLY Revenue C$4 Million Versus C$ 3.2 Million

Knight Therapeutics Inc <GUD.TO>::KNIGHT THERAPEUTICS REPORTS THIRD QUARTER 2019 RESULTS.QTRLY LOSS PER SHARE C$0.021.QTRLY REVENUE C$4 MILLION VERSUS C$ 3.2 MILLION.Q3 EARNINGS PER SHARE VIEW C$0.03, REVENUE VIEW C$3.4 MILLION -- REFINITIV IBES DATA.

Brazil's Biotoscana Appoints Claudio Coracini As Interim CEO After Agreement To Sell Control To Knight Therapeutics- Filing

Oct 28 (Reuters) - Biotoscana Investments SA <GBIO33.SA>::BRAZIL'S BIOTOSCANA APPOINTS CLAUDIO CORACINI AS INTERIM CEO AFTER AGREEMENT TO SELL CONTROL TO KNIGHT THERAPEUTICS- FILING.

Knight Therapeutics To Acquire Grupo Biotoscana

Oct 21 (Reuters) - Knight Therapeutics Inc <GUD.TO>::KNIGHT THERAPEUTICS TO ACQUIRE GRUPO BIOTOSCANA, ESTABLISHING A LATIN AMERICAN GROWTH PLATFORM.KNIGHT THERAPEUTICS INC - DEAL FOR BRL 10.96 PER SHARE.KNIGHT THERAPEUTICS INC - WILL PAY APPROXIMATELY BRL 596 MILLION OR C$189 MILLION IN CASH CONSIDERATION FOR 51.21% CONTROLLING INTEREST IN GBT..KNIGHT THERAPEUTICS - FOLLOWING COMPLETION OF TRANSACTION, KNIGHT WILL LAUNCH A MANDATORY TENDER OFFER TO ACQUIRE REMAINING 48.79% INTEREST IN GBT.KNIGHT THERAPEUTICS INC - EXPECTED CASH CONSIDERATION IS OF APPROXIMATELY BRL 568 MILLION OR C$180 MILLION FOR REMAINING 48.79% INTEREST IN GBT.KNIGHT THERAPEUTICS - WILL ACQUIRE INTEREST IN BIOTOSCANA INVESTMENTS FROM GROUP THAT INCLUDES ADVENT INTERNATIONAL & ESSEX WOODLANDS, AMONG OTHERS.KNIGHT THERAPEUTICS INC - PRIVATE TRANSACTION WILL BE FULLY FUNDED FROM CASH ON KNIGHT'S BALANCE SHEET.KNIGHT THERAPEUTICS INC - WILL BECOME CONTROLLING SHAREHOLDER AND WILL APPOINT ITS REPRESENTATIVES TO BOARD OF GBT.KNIGHT THERAPEUTICS - FOLLOWING COMPLETION OF ACQUISITION OF 100% OF GBT, CO EXPECTS TO PAY AGGREGATE EQUITY PURCHASE PRICE OF BRL 1,164 MILLION/C$369 MILLION.KNIGHT THERAPEUTICS - FOLLOWING COMPLETION OF ACQUISITION OF 100% OF GBT, KNIGHT EXPECTS TO PAY ENTERPRISE VALUE OF BRL 1,318 MILLION OR C$418 MILLION.

Medison Biotech Received Favorable Ruling From Israeli Courts In Response To Litigation Claim Brought By Knight Therapeutics CEO

Aug 26 (Reuters) - Knight Therapeutics Inc <GUD.TO>::MEDISON BIOTECH SAYS RECEIVED FAVORABLE RULING FROM ISRAELI COURTS IN RESPONSE TO LITIGATION CLAIM BROUGHT BY KNIGHT THERAPEUTICS CEO.MEDISON BIOTECH SAYS CALLS ON KNIGHT THERAPEUTICS BOARD, SHAREHOLDERS TO DEMAND JONATHAN GOODMAN NOMINATE SOMEONE OTHER THAN HIMSELF TO MEDISON BOARD.

Knight Therapeutics Reports Second Quarter 2019 Results

Aug 8 (Reuters) - Knight Therapeutics Inc <GUD.TO>::KNIGHT THERAPEUTICS REPORTS SECOND QUARTER 2019 RESULTS.KNIGHT THERAPEUTICS INC - QTRLY BASIC EARNINGS PER SHARE $0.133.KNIGHT THERAPEUTICS INC - QTRLY REVENUES $3.2 MILLION VERSUS $2.2 MILLION.

Knight Therapeutics And Pan-Canadian Pharmaceutical Alliance (PCPA) Reach Agreement For Probuphine For Opioid Dependence

Aug 6 (Reuters) - Knight Therapeutics Inc <GUD.TO>::KNIGHT THERAPEUTICS AND PAN-CANADIAN PHARMACEUTICAL ALLIANCE (PCPA) REACH AGREEMENT FOR PROBUPHINE® FOR OPIOID DEPENDENCE.KNIGHT THERAPEUTICS INC - REACHED AN AGREEMENT WITH PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR A LETTER OF INTENT REGARDING PROBUPHINE.

Knight Therapeutics Announces Health Canada Has Approved Nerlynx For Early-Stage Breast Cancer

July 16 (Reuters) - Knight Therapeutics Inc <GUD.TO>::KNIGHT THERAPEUTICS ANNOUNCES HEALTH CANADA HAS APPROVED NERLYNX ® FOR EARLY-STAGE BREAST CANCER.KNIGHT THERAPEUTICS INC - HAS EXCLUSIVE RIGHT TO COMMERCIALIZE NERLYNX IN CANADA UNDER A LICENSE AGREEMENT WITH PUMA BIOTECHNOLOGY.

Medimetriks Pharmaceuticals Says Company Is Now Free Of Third Party Debt

June 18 (Reuters) - Knight Therapeutics Inc <GUD.TO>::MEDIMETRIKS PHARMACEUTICALS FOCUSES ON ADVANCING MM36 (DIFAMILAST) THROUGH PHASE 3 TRIALS; EXTINGUISHES DEBT OWED TO KNIGHT THERAPEUTICS.MEDIMETRIKS PHARMA - IS IN DISCUSSIONS FOR FINANCING OPTIONS TO ADVANCE MM36 (DIFAMILAST) THROUGH PHASE 3 PIVOTAL TRIALS AND POTENTIAL FDA APPROVAL.MEDIMETRIKS PHARMACEUTICALS - COMPANY EXTINGUISHED FINAL DEBT OWED KNIGHT THERAPEUTICS AND IS NOW FREE OF THIRD PARTY DEBT.

TherapeuticsMD And Theramex Enter Into Exclusive License And Supply Agreement To Commercialize Bijuva And Imvexxy

June 7 (Reuters) - TherapeuticsMD Inc <TXMD.O>::THERAPEUTICSMD AND THERAMEX ENTER INTO EXCLUSIVE LICENSE AND SUPPLY AGREEMENT TO COMMERCIALIZE BIJUVA™ AND IMVEXXY® OUTSIDE THE UNITED STATES.THERAPEUTICSMD INC - AGREEMENT LEVERAGES THERAMEX'S EXTENSIVE WOMEN'S HEALTH CAPABILITIES AND INFRASTRUCTURE TO BENEFIT OF MENOPAUSAL WOMEN OUTSIDE OF U.S..THERAPEUTICSMD INC - THERAPEUTICSMD TO RECEIVE EUR 14 MILLION AS AN UPFRONT FEE.THERAPEUTICSMD INC - IS ELIGIBLE TO RECEIVE UP TO EUR 29.5 MILLION IN REGULATORY AND SALES MILESTONE PAYMENTS, AS WELL AS A ROYALTY ON NET SALES.THERAPEUTICSMD INC - THERAPEUTICSMD IS ALSO ENTITLED TO RECEIVE ROYALTY PAYMENTS ON NET SALES OF BIJUVA AND IMVEXXY IN LICENSED TERRITORIES.THERAPEUTICSMD - CO ENTITLED TO RECEIVE ROYALTY PAYMENTS ON NET SALES OF BIJUVA AND IMVEXXY IN LICENSED TERRITORIES.THERAPEUTICSMD-THERAMEX WILL BE RESPONSIBLE FOR CONDUCTING REGULATORY AND COMMERCIAL ACTIVITIES RELATED TO BIJUVA AND IMVEXXY IN LICENSED TERRITORIES.THERAPEUTICSMD INC - THERAMEX WILL HAVE EXCLUSIVE COMMERCIALIZATION RIGHTS FOR BIJUVA AND IMVEXXY OUTSIDE U.S., EXCLUDING CANADA AND ISRAEL.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up